Advertisement

Topics

NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates For Newly Diagnosed Glioblastoma Patients

20:00 EDT 2 Apr 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates For Newly Diagnosed Glioblastoma Patients

NEXT ARTICLE

More From BioPortfolio on "NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates For Newly Diagnosed Glioblastoma Patients"

Quick Search
Advertisement